Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy

NCT00436917 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00436917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy
Lead sponsor
Mayo Clinic
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2006
Completion date
May 9, 2016
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, osteoporosis